Author’s response to reviews

Title: Predicting for activity of second-line trastuzumab-based therapy in Her2-positive advanced breast cancer

Authors:

Rupert Bartsch (rupert.bartsch@meduniwien.ac.at)
Catharina De Vries (catharina.wenzel@meduniwien.ac.at)
Ursula Pluschnig (ursula.pluschnig@meduniwien.ac.at)
Peter Dubsky (peter.dubsky@meduniwien.ac.at)
Zsuzsanna Bago-Horvath (zsuzsanna.horvath@meduniwien.ac.at)
Simon P Gampenrieder (simon.gampenrieder@meduniwien.ac.at)
Margaretha Rudas (margaretha.rudas@meduniwien.ac.at)
Robert M Mader (robert.mader@meduniwien.ac.at)
Andrea Rottenfusser (andrea.rotenfusser@meduniwien.ac.at)
Christoph Wiltschke (christoph.wiltschke@meduniwien.ac.at)
Michael Gnant (michael.gnant@meduniwien.ac.at)
Christoph C Zielinski (christoph.zielinski@meduniwien.ac.at)
Guenther G Steger (guenther.steger@meduniwien.ac.at)

Version: 3 Date: 21 September 2009

Author’s response to reviews:

Guenther G. Steger
Clinical Division of Oncology
Department of Medicine 1 and Cancer Centre
Medical University of Vienna
Waehringer Guertel 18-20
A-1090 Vienna, Austria
Phone: +43 1 40400 4426
Fax: +43 1 40400 6081
Email: guenther.steger@meduniwien.ac.at

Vienna, 2009-09-21

Dear Mr. Shipley,

On behalf of all co-authors, we submit a new version of our manuscript (“Predicting for activity of second-line trastuzumab-based therapy in Her2-positive advanced breast cancer”) for consideration by your journal.

As suggested, we have now included an acknowledgements section. Furthermore, we have stated that this study was not funded by a pharmaceutical company. We have also changed the formatting of the manuscript according to
the formatting checklist.

We hope that we have met all concerns and the manuscript is acceptable for publication in BMC Cancer.

Sincerely,

Guenther G. Steger R. Bartsch